Financials
Financial year 2025
TAMedecin from Mons, company number BE1015564957, closed financial year 2025 with a result of € 88,583 after tax. For that financial year TAMedecin recorded a gross margin of € 114,882 and equity of € 93,583. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 20, 2026.
€ 93,583
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 88,583
Profit after tax over the fiscal year.
€ 128,893
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 88,583.
People and assets in 2025
€ 47,921
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 48,000
€ 8,983 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 10,456
Supplier invoices still open on the last day of the fiscal year.
€ 25,082
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to TAMedecin?
What happened at TAMedecin in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 88,583. Source: NBB ↗
- New establishment in Soignies. KBO
- Pascal Mercier became a director. NBB
- Natacha Delvallée became a director. NBB
- Tamara Mercier became a director. NBB
- Start of the company according to the CBE. KBO
In short
Paid € 25,082 in corporate taxes since 2025.
A new publication or filing at TAMedecin? We notify you, reason included.
Follow TAMedecinDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind TAMedecin are Pascal Mercier, Natacha Delvallée and Tamara Mercier. Pascal Mercier is also behind INVESTISSEMENTS ET SERVICES AUX MEDIAS. Natacha Delvallée is also behind MEDIA INVEST, INVESTISSEMENTS ET SERVICES AUX MEDIAS and maRadio.be.
Directors
According to the 2025 annual accounts
since 2024
Natacha Delvallée
Director
Also active at: MEDIA INVEST, INVESTISSEMENTS ET SERVICES AUX MEDIAS, maRadio.be
since 2024
Tamara Mercier
Director
since 2024
Establishments
Establishment units
Physical locations of this company
Avenue des Sapins (N.) 29
7020 Mons
Rue Jacquet 10
7061 Soignies
Active since 25 October 2024
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1015.564.957
- VAT number
- BE 1015.564.957
- Registered office
- Avenue des Sapins (N.) 29, 7020 Mons
- Names & denominations
- TAMedecin
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 25 October 2024
- Peppol
- Active · Active since 30 Sept 2025